Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Revelation Biosciences, Inc. - SIC # 3840 -
Ticker
Exchange
SIC #
Website
Latest Ticker
REVB
Nasdaq
3840
www.revbiosciences.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Revelation Biosciences, Inc.
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Jan 12th, 2026 3:00 pm
Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development
- Jan 7th, 2026 7:00 am
Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting
- Dec 1st, 2025 7:00 am
Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year
- Nov 20th, 2025 7:00 am
REVB Ready to Advance Groundbreaking Treatment
- Nov 7th, 2025 4:07 am
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025
- Nov 6th, 2025 2:15 pm
Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date
- Oct 29th, 2025 7:00 am
Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025
- Oct 15th, 2025 3:00 pm
Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds
- Sep 11th, 2025 6:30 am
Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data
- Sep 10th, 2025 5:20 am
Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data
- Sep 9th, 2025 2:55 pm
Groundbreaking Results from REVB Point to Relief for Millions
- Sep 9th, 2025 6:08 am
Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study
- Sep 9th, 2025 6:00 am
REVB To Release Test Results This Quarter
- Aug 8th, 2025 6:04 am
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025
- Aug 8th, 2025 4:30 am
Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research
- Jul 24th, 2025 7:00 am
Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study
- Jul 16th, 2025 7:00 am
The early winner in the 'Dexit' war for corporate relocations: Nevada
- Jul 10th, 2025 2:00 am
Investors Should Look at REVB as Top-Line Results Approach
- Jul 9th, 2025 5:54 am
Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025
- Jul 1st, 2025 3:26 pm
Scroll